FEROX STRATEGIES

Lobbying for RARE DISEASE COMPANY COALITION · Healthcare

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $50,000.00 income · posted Jan 20, 2026

Lobbying activity 3

Taxation/Internal Revenue Code

General issues related to rare disease treatment development.

Health Issues

General issues related to rare disease treatment.

Trade (domestic/foreign)

General issues related to tariffs.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.